Capital Research Global Investors Has $28.80 Million Holdings in Icon Plc $ICLR

Capital Research Global Investors boosted its stake in Icon Plc (NASDAQ:ICLR) by 69.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,563 shares of the medical research company’s stock after purchasing an additional 67,480 shares during the period. Capital Research Global Investors’ holdings in Icon were worth $28,799,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Allworth Financial LP lifted its holdings in Icon by 64.4% during the 2nd quarter. Allworth Financial LP now owns 1,396 shares of the medical research company’s stock worth $203,000 after buying an additional 547 shares during the period. Geode Capital Management LLC raised its position in shares of Icon by 2.6% during the second quarter. Geode Capital Management LLC now owns 84,370 shares of the medical research company’s stock worth $12,272,000 after acquiring an additional 2,159 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Icon by 21.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock worth $545,730,000 after acquiring an additional 650,379 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Icon by 12.3% in the second quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company’s stock worth $2,322,000 after acquiring an additional 1,743 shares during the period. Finally, Raiffeisen Bank International AG boosted its holdings in Icon by 7.1% in the second quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company’s stock valued at $1,094,000 after acquiring an additional 500 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Bank of America restated an “underperform” rating and set a $75.00 price target on shares of Icon in a report on Thursday, February 12th. Citigroup reduced their price objective on shares of Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research note on Wednesday. Rothschild & Co Redburn set a $100.00 price objective on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Jefferies Financial Group set a $135.00 target price on shares of Icon and gave the stock a “buy” rating in a research note on Monday, February 23rd. Finally, Truist Financial reaffirmed a “hold” rating and set a $222.00 price target (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Six investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Icon has a consensus rating of “Hold” and an average target price of $146.80.

Icon Stock Performance

NASDAQ:ICLR opened at $97.45 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a fifty day moving average of $145.89 and a 200-day moving average of $166.01. The firm has a market capitalization of $7.87 billion, a P/E ratio of 13.19, a P/E/G ratio of 2.70 and a beta of 1.35.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.